Phase 1b/2a clinical trial assessing safety and efficacy of LTX-001 in adults with schizophrenia initiated

启动评估LTX-001在成年精神分裂症患者中安全性和有效性的1b/2a期临床试验

Financing advances LTX-001 through initial readout from Phase 1b/2a trial and progresses LTX-002 through additional dosing cohorts of ongoing Phase 1/2 trial in ALS

融资用于推进LTX-001完成Ib/IIa期试验的初步数据读出，并推动LTX-002在肌萎缩侧索硬化症（ALS）正在进行的I/II期试验中增加更多剂量队列。

WORCESTER, Mass.

马萨诸塞州伍斯特

,

，

Aug. 17, 2026

2026年8月17日

/PRNewswire/ -- Leal Therapeutics, Inc. (Leal), a clinical-stage biopharmaceutical company developing first-in-class neuro-metabolic therapeutics, today announced a second close of $30 million of its Series A financing. The round includes new investor Eli Lilly and Company (Lilly), in addition to existing investors OrbiMed, Newpath Partners, Euclidean Capital, SV Health Investors' Dementia Discovery Fund (DDF), Chugai Venture Fund, Alexandria Venture Investments, and PhiFund..

/美通社/ -- 致力于开发首创神经代谢疗法的临床阶段生物制药公司Leal Therapeutics, Inc.（简称“Leal”）今日宣布，其A轮融资完成第二次交割，金额为3,000万美元。本轮融资引入了新投资者礼来公司（Lilly），现有投资者包括OrbiMed、Newpath Partners、Euclidean Capital、SV Health Investors旗下的痴呆症发现基金（DDF）、Chugai Venture Fund、Alexandria Venture Investments以及PhiFund。

Proceeds from the second closing of Series A financing will be used to advance LTX-001 through an initial readout of its Phase 1b/2a clinical trial in schizophrenia patients, as well as progress LTX-002 through additional dosing cohorts in an ongoing Phase 1/2 clinical trial in amyotrophic lateral sclerosis (ALS)..

A轮融资第二次交割所得款项将用于推动LTX-001在精神分裂症患者中的Ib/IIa期临床试验初步数据读出，以及推进LTX-002在正在进行的肌萎缩侧索硬化症（ALS）I/II期临床试验中更多剂量队列的研究。

LTX-001, a first-in-class brain-penetrant oral GLS1 inhibitor, has completed single ascending dose (SAD) and multiple ascending dose (MAD) Phase 1 trials and demonstrated a favorable safety and tolerability profile and dose dependent CNS target engagement. Leal today also announces the initiation of the Phase 1b/2a trial (NCT07734493) in adults with schizophrenia, with initial data expected by year-end. .

LTX-001 是一款首创的、可穿透血脑屏障的口服 GLS1 抑制剂，已完成单剂量递增（SAD）和多剂量递增（MAD）的 I 期临床试验，并展现出良好的安全性和耐受性以及剂量依赖性的中枢神经系统靶点结合。Leal 今日还宣布启动针对成年精神分裂症患者的 Ib/IIa 期临床试验（NCT07734493），预计将在年底前获得初步数据。

LTX-002 is an intrathecally delivered antisense oligonucleotide designed to restore healthy sphingolipid levels in the central nervous system (CNS) by targeting SPTLC1.  LTX-002 is being investigated in NeurALS, a Phase 1/2 trial (NCT07660614) in adults with ALS.

LTX-002 是一种鞘内给药的反义寡核苷酸，旨在通过靶向 SPTLC1 来恢复中枢神经系统（CNS）中健康的鞘脂水平。LTX-002 正在 NeurALS 研究中接受评估，这是一项针对肌萎缩侧索硬化症（ALS）成年患者的 1/2 期临床试验（NCT07660614）。

'We are very excited to partner with our top-tier syndicate of investors which now includes Lilly', said Asa Abeliovich, M.D., Ph.D., founder and chief executive officer of Leal. 'This funding will support us through key clinical milestones for LTX-001 in schizophrenia, including initial data from the now ongoing Phase 1b/2a trial, and LTX-002 in ALS, while also advancing our preclinical pipeline towards clinical development.'.

“我们非常兴奋能与包括礼来在内的顶级投资者联盟合作，”Leal公司创始人兼首席执行官Asa Abeliovich医学博士、哲学博士表示。“这笔资金将支持我们实现LTX-001在精神分裂症治疗方面的关键临床里程碑，包括目前正在进行中的1b/2a期试验的初步数据，以及LTX-002在肌萎缩侧索硬化症（ALS）治疗方面的进展，同时推动我们的临床前管线向临床开发阶段迈进。”

About Leal Therapeutics:

关于Leal Therapeutics：

Leal Therapeutics is a biotechnology company dedicated to developing novel neuro-metabolic therapeutics for patients with high-need central nervous system disorders. Leal was launched in 2021 and is headquartered in Worcester, Mass.  Leal's lead programs address the critical intersection between CNS and metabolic disorders.  The Leal team has particular expertise in CNS therapeutic development, as well as leveraging human genetics, functional genomics and biomarker analyses to support our mission.  Leal has the technological capability to develop and produce small molecule and nucleic acid CNS therapeutics, and is also developing a next-generation CNS delivery platform utilizing antibody-like shuttle technology to enable the transport of peripherally administered therapeutics to the brain..

Leal Therapeutics 是一家生物技术公司，致力于开发针对高需求中枢神经系统疾病患者的新型神经代谢疗法。Leal 成立于2021年，总部位于马萨诸塞州伍斯特市。Leal 的核心项目聚焦于中枢神经系统（CNS）与代谢性疾病之间的关键交叉领域。Leal 团队在中枢神经系统药物开发方面拥有深厚的专业积累，并擅长利用人类遗传学、功能基因组学和生物标志物分析来支持其使命。Leal 具备开发和生产小分子及核酸类中枢神经系统药物的技术能力，同时也在开发一种下一代中枢神经系统递送平台，该平台采用抗体样穿梭技术，以实现外周给药的药物向脑部的转运。

Media contact:

媒体联系人：

Tehya Frank,

特娅·弗兰克，

[email protected]

[email protected]

347-640-1334

347-640-1334

SOURCE Leal Therapeutics

来源：Leal Therapeutics

21

二十一

%

百分之

more press release views with

更多新闻稿浏览量

Request a Demo

申请演示